8-K: Gilead Q2 Earnings Beat, Raises 2025 Outlook

Gilead Sciences reports strong second quarter 2025 financial results, driven by HIV and oncology sales, leading to an increase in full-year revenue and earnings guidance.

Summary

• Total second quarter 2025 revenue increased 2% year-over-year to $7.1 billion.
• Product sales excluding Veklury increased 4% year-over-year to $6.9 billion.
• Diluted earnings per share (EPS) was $1.56 in Q2 2025, up from $1.29 in Q2 2024.
• Non-GAAP diluted EPS remained flat at $2.01 in Q2 2025 compared to Q2 2024.
• HIV product sales increased 7% to $5.1 billion, primarily driven by Biktarvy (up 9% to $3.5 billion) and Descovy (up 35% to $653 million).
• Trodelvy sales increased 14% to $364 million.
• Veklury sales decreased 44% to $121 million due to lower COVID-19 hospitalizations.
• Cell Therapy product sales decreased 7% to $485 million due to competitive headwinds.
• Liver Disease portfolio sales decreased 4% to $795 million, primarily due to lower HCV sales.
• An in-process research and development (IPR&D) impairment charge of $190 million was recorded related to assets from the MYR GmbH acquisition.
• Cash, cash equivalents, and marketable debt securities stood at $7.1 billion as of June 30, 2025, down from $10.0 billion at December 31, 2024.
• Operating cash flow for Q2 2025 was $827 million, net of a final $1.3 billion transition tax payment.
• Gilead paid $994 million in dividends and repurchased $527 million of common stock during the quarter.
• The Board authorized a new $6.0 billion stock repurchase program, commencing upon completion of the previous program.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance with increased revenue and EPS, driven by key product growth in HIV and oncology. The raised full-year guidance and significant new drug approval (Yeztugo) are highly positive. While there are declines in Veklury and Cell Therapy sales, and an IPR&D impairment, these are largely offset by the overall positive momentum and strategic advancements.

Positives

• Total revenue increased 2% year-over-year to $7.1 billion.
• Product sales excluding Veklury increased 4% year-over-year to $6.9 billion, indicating strong core business growth.
• GAAP diluted EPS increased to $1.56 from $1.29 in the prior year, driven by net unrealized gains on securities and higher product sales.
• HIV product sales grew 7% to $5.1 billion, with Biktarvy sales up 9% to $3.5 billion and Descovy sales up 35% to $653 million.
• Trodelvy sales increased 14% to $364 million, reflecting strong demand.
• Received U.S. FDA approval for Yeztugo (lenacapavir) as the world's first twice-yearly HIV prevention option.
• Received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending lenacapavir for HIV PrEP.
• Announced a strategic partnership with the Global Fund to accelerate access to lenacapavir for HIV PrEP in lowand lower-middle-income countries at no profit.
• Presented positive topline results from the Phase 3 ASCENT-03 trial evaluating Trodelvy in 1L metastatic triple-negative breast cancer.
• The Board declared a quarterly dividend of $0.79 per share for Q3 2025, an increase from $0.77 in Q2 2024.
• A new $6.0 billion stock repurchase program was authorized, demonstrating commitment to shareholder returns.
• Reached a final settlement agreement with the U.S. Department of Justice resolving a legacy compliance matter, which was accrued in 2024.
• Named by TIME as a 2025 Most Influential Company.

Negatives

• Non-GAAP diluted EPS remained flat at $2.01 despite higher product sales, offset by higher R&D expenses.
• Veklury sales decreased 44% to $121 million due to lower rates of COVID-19-related hospitalizations.
• Cell Therapy product sales decreased 7% to $485 million, reflecting ongoing competitive headwinds.
• Yescarta sales decreased 5% to $393 million, primarily driven by lower demand.
• Tecartus sales decreased 14% to $92 million, primarily reflecting lower demand.
• Liver Disease portfolio sales decreased 4% to $795 million, primarily driven by lower HCV sales.
• A pre-tax in-process research and development (IPR&D) impairment charge of $190 million was recorded related to assets acquired as part of the MYR GmbH acquisition.
• Cash, cash equivalents, and marketable debt securities decreased to $7.1 billion as of June 30, 2025, from $10.0 billion at December 31, 2024.

Risks

• Ability to achieve full-year 2025 financial guidance is subject to uncertainty regarding Veklury revenues, impact of the Inflation Reduction Act, and changes in U.S. regulatory, legislative, and trade policies.
• Challenges in accelerating or sustaining revenues for virology, oncology, and other programs.
• Risks in realizing the potential benefits of acquisitions, collaborations, or licensing arrangements, including those with MYR, Arcellx, Kymera, and the Global Fund.
• Uncertainty regarding patent protection and estimated loss of exclusivity for products and product candidates.
• Potential for unfavorable results from ongoing and additional clinical trials, or inability to initiate, progress, or complete trials within anticipated timeframes.
• Risk that safety and efficacy data from clinical trials may not warrant further development of product candidates.
• Ability to resolve issues cited by the FDA in the clinical hold on GS-1720 and GS-4182 trials to the FDA's satisfaction, and the risk that the clinical hold may not be removed in a timely manner or at all.
• Challenges in submitting new drug applications for new product candidates or expanded indications within anticipated timelines.
• Risks in receiving or maintaining regulatory approvals in a timely manner or at all, including for additional approvals for lenacapavir for HIV PrEP, and potential for significant limitations on use or withdrawal of approvals.
• Difficulties in successfully commercializing products.
• Potential disruptions to the manufacturing and supply chain of products.
• Pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts.
• Risk of a larger than anticipated shift in payer mix to more highly discounted payer segments.
• Market share and price erosion caused by the introduction of generic versions of Gilead products.
• Risk that physicians and patients may not perceive advantages of Gilead's products over other therapies, potentially leading to reluctance in prescribing.
• Challenges in effectively managing the access strategy relating to lenacapavir for HIV PrEP.

Future Outlook

Gilead has increased its full-year 2025 guidance for total product sales to a range of $28.3 billion to $28.7 billion, and product sales excluding Veklury to $27.3 billion to $27.7 billion. Diluted EPS guidance is raised to $5.85 to $6.15, and non-GAAP diluted EPS guidance is raised to $7.95 to $8.25. The company anticipates continued innovation and growth across its core therapeutic areas, despite a reduced outlook for Veklury sales.

Management Comments

• "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the worlds first twice-yearly HIV prevention option."
• "Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio."
• "As we enter the third quarter, we are increasing revenue and earnings guidance for the year, and look forward to delivering continued innovation and growth across our core therapeutic areas."

Industry Context

Gilead's strong performance in HIV, particularly with Biktarvy and the approval of Yeztugo, positions it well in the competitive HIV prevention and treatment market. The decline in Veklury sales reflects the broader trend of decreasing COVID-19 related hospitalizations and the shift away from pandemic-era treatments. Growth in oncology, specifically with Trodelvy, indicates successful diversification efforts, while challenges in Cell Therapy sales highlight intense competition in that segment. The strategic partnership with the Global Fund for HIV PrEP access aligns with global health initiatives and could expand market reach in developing countries.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking against industry standards. However, Gilead's continued dominance in the HIV market with Biktarvy's 9% growth and Descovy's 35% growth suggests strong competitive positioning against other HIV drug manufacturers like GSK (Dovato, Juluca) and ViiV Healthcare.
• The 14% growth in Trodelvy sales indicates strong uptake in the oncology space, where it competes with other antibody-drug conjugates and chemotherapy regimens from companies such as AstraZeneca (Enhertu) and Seagen (Padcev).
• The decline in Cell Therapy sales (Yescarta down 5%, Tecartus down 14%) suggests Gilead faces significant competitive pressures from other CAR T-cell therapies, such as Novartis' Kymriah and Bristol Myers Squibb's Abecma and Breyanzi, which have also been expanding their indications and market presence.
• The FDA approval of Yeztugo as a twice-yearly HIV PrEP option is a significant competitive advantage, offering a differentiated dosing regimen compared to daily oral PrEP options from Gilead (Descovy, Truvada) and generic alternatives, potentially expanding the PrEP market and improving adherence.

Corporate Governance

Legal Proceedings

• Reached a final settlement agreement with the U.S. Department of Justice resolving a legacy compliance matter. This settlement was accrued in 2024 and reported under SG&A expenses.

Stakeholder Impact

• Shareholders: Positive impact due to increased full-year guidance, a declared dividend, and authorization of a new $6.0 billion stock repurchase program, indicating strong financial health and commitment to capital returns.
• Patients: Positive impact from the FDA approval of Yeztugo, the world's first twice-yearly HIV prevention option, and the strategic partnership with the Global Fund to accelerate access to lenacapavir for HIV PrEP in lowand lower-middle-income countries.
• Employees: Generally positive outlook due to strong company performance and strategic advancements, though no direct impact on employment or benefits is specified.
• Customers (Healthcare Providers/Payers): Continued access to a diverse portfolio of medicines, including new and growing products like Yeztugo, Biktarvy, and Trodelvy, but also potential for pricing and reimbursement pressures.

Next Steps

• The recommendation for lenacapavir for HIV PrEP from the European Medicines Agency's Committee for Medicinal Products for Human Use will be reviewed by the European Commission.
• Gilead will continue to work towards resolving the FDA clinical hold on the GS-1720 and GS-4182 HIV treatment trials.
• The new $6.0 billion stock repurchase program will commence upon the completion of the previously approved program.
• Future dividends will be subject to Board approval.
• Gilead will host a conference call at 1:30 p.m. Pacific Time on August 7, 2025, to discuss results.

Key Dates

Recommendation

Gilead's Q2 2025 results demonstrate robust growth in its core HIV franchise and promising oncology assets like Trodelvy, which are key drivers for future revenue. The FDA approval of Yeztugo, a first-in-class twice-yearly HIV prevention option, represents a significant competitive advantage and market expansion opportunity. Management's decision to raise full-year revenue and EPS guidance, coupled with the authorization of a substantial $6.0 billion stock repurchase program and a dividend increase, signals strong confidence in the company's financial trajectory and commitment to shareholder value. While there are headwinds in Veklury and Cell Therapy, the overall strategic direction and financial performance indicate a compelling investment opportunity.

Keywords

Biopharmaceutical, HIV, Oncology, Viral Hepatitis, COVID-19, Inflammation, Biktarvy, Descovy, Trodelvy, Yeztugo, Lenacapavir, Veklury, Cell Therapy, Earnings, Guidance, FDA Approval, Clinical Trials, Pharmaceuticals